KRL74

KRL74 is a cyclic peptide inhibitor for interaction between the p6 domain of the HIV Gag protein and the UEV domain of the human TSG101 protein (p6/UEV) with an IC50 of 5.44 μM and a Kd of 11.9 μM. KRL74 inhibits the budding process of HIV from host cells with an IC50 of 2 μM in virus-like particle (VLP) budding assay[1].

2423969-43-9

12352209

HIV

Anti-infection

COVID-19-anti-virus

Infection

O=C([C@@H](NC([C@](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC1=O)C)=O)C(C)C)=O)CO)=O)=O)CC2=CNC3=CC=CC=C23)=O)([H])[C@@H](C)CC)=O)CC4=CC=C(C=C4)Cl)N[C@H]1CC5=CNC6=CC=CC=C56

C50H61ClN10O9

981.53

[1]Lennard KR, et al., Development of a Cyclic Peptide Inhibitor of the p6/UEV Protein-Protein Interaction. ACS Chem Biol. 2019 Sep 20;14 (9) :1874-1878.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10845/

Peptides

No Development Reported